Cancer Discovery 2019-Aug
Merck LAPs Up Tilos for Its TGFβ-Targeting Tech.
Solo los usuarios registrados pueden traducir artículos
Iniciar sesión Registrarse
El enlace se guarda en el portapapeles.
Palabras clave
Abstracto
Merck will spend up to $773 million to acquire Tilos Therapeutics, a 3-year-old startup with a series of preclinical-stage antibodies that prevent the activation and release of TGFβ, a cytokine involved in thwarting the effectiveness of cancer immunotherapies.